ONCE-DAILY ORAL

LUMAKRAS® (sotorasib) tablets
320 mg | 240 mg | 120 mg

+

Vectibix® (panitumumab)
100mg/5ml | 20mg/ml for injection

A patient guide to

Getting started with LUMAKRAS® + Vectibix®

Let’s get started →





Please see **Prescribing Information** for LUMAKRAS®, and
Important Safety Information for LUMAKRAS® and Vectibix® on pages 12-16.

Welcome to your LUMAKRAS® + Vectibix® treatment journey.

In this guide, you will find information about each treatment and the support resources available to help you navigate your journey on **LUMAKRAS®** + **Vectibix®**.

Two types of treatment, one destination for support

It is important to understand that, although your doctor prescribed LUMAKRAS® + Vectibix® to be taken in combination, there are separate steps you need to follow to get each treatment.



LUMAKRAS® is a pill that you swallow and is usually taken at home



Vectibix® is given by scheduled infusion and takes place at your infusion center

AMGEN® Support+

We're right here, right when you need us.

With financial support resources and other helpful patient support services, we are here to help you along the way.

Please see **Prescribing Information** for LUMAKRAS®, and Important Safety Information for LUMAKRAS® and Vectibix® on pages 12-16.

ONCE-DAILY ORAL LUMAKRAS® (sotorasib) tablets 320 mg | 240 mg | 120 mg + Vectibix® (panitumumab) 100mg/5ml | 20mg/ml for injection

Getting started on your LUMAKRAS® + Vectibix® treatment journey



1 Your doctor's office initiates your journey



Checks your insurance plus discusses costs and support resources for you



Sends **LUMAKRAS®** prescription to be filled and orders **Vectibix®**



Schedules your first **Vectibix®** infusion

2 Starting LUMAKRAS®



LUMAKRAS® will be shipped to your doctor's office or your house



You will be taking your **LUMAKRAS®** before you receive your first infusion. Your doctor will tell you when to take it






3 Starting Vectibix®



You go to your first **Vectibix®** infusion appointment



You schedule follow-up **Vectibix®** appointments



You and your doctor discuss continued treatment plan

Please see **Prescribing Information** for LUMAKRAS®, and Important Safety Information for LUMAKRAS® and Vectibix® on pages 12-16.

ONCE-DAILY ORAL LUMAKRAS® (sotorasib) tablets 320 mg | 240 mg | 120 mg + Vectibix® (panitumumab) 100mg/5ml | 20mg/ml for injection

Checking insurance coverage



Your doctor’s office will check your insurance coverage for **LUMAKRAS®**. You will get the prescription one of two ways:

- By mail
- At your doctor’s office



Your doctor’s office will check your insurance coverage for **Vectibix®**. The doctor will discuss next steps prior to you coming back for an infusion.

Your insurance company may need a prior authorization from your doctor for LUMAKRAS® + Vectibix®. Your healthcare team will work together to complete and submit any necessary paperwork on your behalf.

What is a prior authorization?

A **prior authorization** is a process the insurance company uses to determine if they will cover your therapy. Your doctor's office will submit certain information to help the insurance company make this decision.

Please see **Prescribing Information** for LUMAKRAS®, and Important Safety Information for LUMAKRAS® and Vectibix® on pages 12-16.

ONCE-DAILY ORAL
LUMAKRAS® (sotorasib) tablets
320 mg | 240 mg | 120 mg
+
Vectibix® (panitumumab)
100mg/5ml | 20mg/ml for injection


AMGEN® Support+

Coverage support resources your doctor's team may use to help you.



HCP Support Center

Amgen® SupportPlus Representatives can assist offices with patient coverage questions, prior authorizations, co-pay programs, and more.



Amgen® Access Specialist

The office can reach out to an Amgen Access Specialist who can provide coverage and access support, including:

- Help with navigating prior authorization appeals and fulfillment processes
- Educating on payer requirements and necessary documentation for individual patient support
- Answers to general questions about Amgen® SupportPlus programs and other available resources

Call (866) 264-2778, Monday – Friday, 9 am to 8 pm ET to learn more.

Visit Amgen® SupportPlus →

Paying for treatment



You pay the pharmacy or doctor's office for **LUMAKRAS®**.

- Cost varies depending on insurance coverage
- Cost support resources on next page could help significantly reduce the amount you pay for **LUMAKRAS®**



You pay the infusion clinic for **Vectibix®** after your appointment.

- Cost varies depending on insurance coverage
- Cost support resources on next page could help significantly reduce the amount you pay for **Vectibix®**

What is a co-pay?

A **co-pay** is a fixed amount you pay for a covered medication after you've paid any deductible.

The Amgen® SupportPlus Co-Pay program may help cover costs for both **LUMAKRAS®** and **Vectibix®** with one co-pay card. See next page for details.

Please see **Prescribing Information** for LUMAKRAS®, and Important Safety Information for LUMAKRAS® and Vectibix® on pages 12-16.

ONCE-DAILY ORAL
LUMAKRAS® (sotorasib) tablets
320 mg | 240 mg | 120 mg
+
Vectibix® (panitumumab)
100mg/5ml | 20mg/ml for injection

AMGEN® Support+

Cost support resources



Amgen® SupportPlus Co-Pay Program

The Amgen SupportPlus Co-Pay Program may help patients with private or commercial insurance lower their out-of-pocket costs

- Pay as little as $0* out-of-pocket for each dose or cycle of LUMAKRAS® and Vectibix®
- Can be applied to deductible, co-insurance, and co-payment
- No income eligibility requirement



What if I don’t have private or commercial insurance (eg, self-purchased or through an employer)?

Amgen® SupportPlus can provide information about independent nonprofit foundations that may be able to help.†

*Eligibility criteria and program maximums apply.
See **AmgenSupportPlus.com/copay** for full Terms and Conditions.

†Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit’s criteria. Amgen has no control over these programs and provides information as a courtesy only.

Call (866) 264-2778, Monday – Friday, 9 am to 8 pm ET to learn more.

Visit Amgen® SupportPlus →

Starting and staying on treatment



Ask your doctor when you should start taking **LUMAKRAS®** at home.

Remember, you will get **LUMAKRAS®**:

- By mail (from specialty pharmacy)
- At your doctor's office

Discuss your plan for refills and continued treatment with your doctor's office.



Your first **Vectibix®** infusion appointment will be scheduled by your doctor's office.

They will let you know:

- Appointment location (eg, infusion center)
- Expectations and preparations

Future **Vectibix®** infusion appointments will be scheduled as directed by your doctor.

What is a specialty pharmacy?

A **specialty pharmacy** focuses on medications like **LUMAKRAS®** that you may not be able to pick up at your regular local pharmacy.

Please see **Prescribing Information** for LUMAKRAS®, and Important Safety Information for LUMAKRAS® and Vectibix® on pages 12-16.

ONCE-DAILY ORAL LUMAKRAS® (sotorasib) tablets 320 mg | 240 mg | 120 mg + Vectibix® (panitumumab) 100mg/5ml | 20mg/ml for injection

A recap of how to get LUMAKRAS® + Vectibix®

The steps your office will take:

- [ ] My doctor's office will check my insurance coverage for both **LUMAKRAS®** + **Vectibix®.**
- [ ] My doctor's office will discuss cost support resources available for both **LUMAKRAS®** + **Vectibix®** with me.
- [ ] My doctor's office will help coordinate when I get **LUMAKRAS®** and schedule my first **Vectibix®** infusion.

The steps you will take:

- [ ] I will get **LUMAKRAS®** in the mail or by picking up at my doctor's office.
- [ ] I will start taking **LUMAKRAS®** at home when instructed by my doctor.
- [ ] I will go to my first **Vectibix®** infusion.

Your doctor's office will discuss refills and follow-up appointments with you. **Amgen® SupportPlus** is also here to help, with information and resources to help you manage your journey.

Please see **Prescribing Information** for LUMAKRAS®, and Important Safety Information for LUMAKRAS® and Vectibix® on pages 12-16.

ONCE-DAILY ORAL LUMAKRAS® (sotorasib) tablets 320 mg | 240 mg | 120 mg + Vectibix® (panitumumab) 100mg/5ml | 20mg/ml for injection

AMGEN® Support+

Support resources for your treatment journey

With financial support resources and other helpful patient support services, we are here to help you along the way.

Visit **AmgenSupportPlus.com** where you'll find support information and resources personalized for each Amgen medication.

- Select **LUMAKRAS®** or **Vectibix®**
- Choose your support resource
- Follow online enrollment instructions or call to sign up

Call (866) 264-2778, Monday – Friday, 9 am to 8 pm ET to learn more.

Visit Amgen® SupportPlus →

What is LUMAKRAS®?

LUMAKRAS® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC):

- that has spread to other parts of the body or cannot be removed by surgery, and
- whose tumor has an abnormal KRAS G12C gene, and
- who have received at least one prior treatment for their cancer.

Your healthcare provider will perform a test to make sure that LUMAKRAS® is right for you.
It is not known if LUMAKRAS® is safe and effective in children.


IMPORTANT SAFETY INFORMATION FOR LUMAKRAS®

What should I tell my healthcare provider before taking LUMAKRAS®?

- Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
  - have liver problems
  - have lung or breathing problems other than lung cancer
  - are pregnant or plan to become pregnant. It is not known if LUMAKRAS® will harm your unborn baby.
  - are breastfeeding or plan to breastfeed. It is not known if LUMAKRAS® passes into your breast milk. Do not breastfeed during treatment with LUMAKRAS® and for 1 week after the last dose.
- Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, dietary and herbal supplements. LUMAKRAS® can affect the way some other medicines work, and some other medicines can affect the way LUMAKRAS® works.
- Especially tell your healthcare provider if you take antacid medicines, including Proton Pump Inhibitor (PPI) medicines or H_2 blockers during treatment with LUMAKRAS®. Ask your healthcare provider if you are not sure.

LUMAKRAS® may cause serious side effects, including:

- Liver problems: LUMAKRAS® may cause abnormal liver blood test results. Your healthcare provider should do blood tests before starting and during treatment with LUMAKRAS® to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including: your skin or the white part of your eyes turns yellow



IMPORTANT SAFETY INFORMATION FOR LUMAKRAS® (cont'd)

(jaundice), dark or "tea-colored" urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, and pain, aching, or tenderness on the right side of your stomach-area (abdomen).

- Lung or breathing problems: LUMAKRAS® may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough or fever.
- Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LUMAKRAS® if you develop side effects.

The most common side effects

- The most common side effects of LUMAKRAS® include diarrhea, muscle or bone pain, nausea, tiredness, liver problems, cough, changes in liver function tests, and changes in certain blood tests.
- These are not all the possible side effects of LUMAKRAS®. Call your doctor for medical advice about side effects.

Your healthcare provider will perform a test to make sure that LUMAKRAS® is right for you. It is not known if LUMAKRAS® is safe and effective in children.

Please see LUMAKRAS® **Patient Information**.

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR VECTIBIX®


INDICATIONS

Vectibix is indicated for treating adult patients with wild-type *RAS* metastatic colorectal cancer (cancer that has spread outside the colon and rectum). *RAS* status is determined by an FDA-approved test. Wild-type *RAS* is a cancer without mutations in the *KRAS* and *NRAS* genes.

Vectibix can be used:

- As a first-time treatment given with chemotherapy called FOLFOX (folinic acid, fluorouracil, oxaliplatin)
- Alone, following disease progression with the following chemotherapies: fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy.

Vectibix, when given with FOLFOX or alone, is not to be used to treat patients with tumors that have mutations in the *RAS* gene (called *RAS* mutant). Vectibix is not to be used when the *RAS* mutation status is unknown. Talk to your doctor about your *RAS* status.



INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR VECTIBIX® (cont'd)

Vectibix is a prescription medicine used in adults in combination with a prescription medicine called Lumakras (sotorasib) to treat colon or rectal cancer (CRC) that has spread to other parts of the body **and** whose tumor has an abnormal *KRAS G12C* gene, **and** who have previously received certain chemotherapy medicines.

IMPORTANT SAFETY INFORMATION

Vectibix can cause skin side effects, which may be severe. In a clinical study, nearly all patients (90%) taking Vectibix experienced skin rash or other skin reactions. Skin reactions included but were not limited to:

- Acne-like skin rash
- Itching
- Redness
- Skin rash
- Skin peeling
- Nail infections at the side of the nail beds of the fingers or toes
- Dry skin
- Openings in the skin

Of these patients, 15% had severe skin reactions that involved, for some, pain, disfigurement, ulceration, or loss of outer layers of skin when receiving Vectibix alone. Some patients who developed severe skin reactions also developed infections in the blood, skin, fat, or tissue that sometimes resulted in death.

Your doctor may need to make changes to your dose to address your side effects or, in the event of severe or life-threatening side effects, stop Vectibix treatment. It is important that you tell your doctor right away if you have any skin reactions or any signs of infection (such as chills, fever, or increased redness or swelling of an existing skin reaction).

Patients who have metastatic colorectal cancer with *RAS*-mutant tumors should not receive Vectibix with FOLFOX or alone. Several clinical trials have been done evaluating treatments that block part of the pathway that increases tumor cell growth (anti-epidermal growth factor receptor [EGFR]). Anti-EGFR treatments include Vectibix and Erbitux (cetuximab). In studies of these medicines, patients with *RAS*-mutant tumors experienced serious side effects without any benefit from the treatment. In one study, patients with *RAS*-mutant tumors who received Vectibix + FOLFOX did not live as long as patients who received FOLFOX alone.

Some patients who were taking Vectibix® developed low levels of certain electrolytes, including magnesium, calcium and potassium. Some patients also developed high levels of potassium. Your doctor may check the levels of these electrolytes in your blood while you are on treatment and for up to 2 months after you finish treatment. Your doctor may add other oral or intravenous medications to your Vectibix® treatment.

ONCE-DAILY ORAL
LUMAKRAS® (sotorasib) tablets
320 mg | 240 mg | 120 mg
+
Vectibix® (panitumumab)
100mg/5ml | 20mg/ml for injection

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR VECTIBIX® (cont'd)

Vectibix is given by infusion into a vein. Some patients may develop an infusion reaction, which can be severe and in rare cases has resulted in death. In one clinical study, infusion reactions developed in 4% of patients, and 1% of patients experienced serious infusion reactions. Infusion reactions included:

- Fever
- Chills
- Shortness of breath
- Throat spasms
- Low blood pressure

Depending on how severe the reaction is, your doctor may decide to slow the rate of the infusion, stop the infusion, or stop your Vectibix® treatment completely.

Tell your doctor right away if you experience severe diarrhea or dehydration. Some patients treated with Vectibix and chemotherapy developed kidney failure and other complications because of severe diarrhea and dehydration.

Lung disease, including fatal lung disease, occurred in 1% or less of patients who had taken Vectibix. Tell your doctor if you have problems breathing, wheezing, or a cough that doesn't go away or keeps coming back. If you have had lung problems in the past, be sure to tell your doctor. Your doctor may decide to stop Vectibix® treatment.

Being in the sun may make skin reactions worse. Wear sunscreen and protective clothing (such as a hat) and avoid direct sunlight while you are on treatment with Vectibix. Tell your doctor if you have new or worsening skin reactions.

Inflammation of the eye and injury to the cornea have been reported. Tell your doctor if you have any vision changes or eye problems. If you experience any of these side effects or they worsen, your doctor should interrupt or discontinue Vectibix.

In a study of patients treated for mCRC, the addition of Vectibix to the combination of Avastin (bevacizumab) and chemotherapy caused patients to experience severe side effects and to not live as long as patients receiving only Avastin and chemotherapy. Do not take Avastin with Vectibix.

- Some moderate to severe side effects happened at a higher rate for Vectibix patients, including acne-like rash, diarrhea, dehydration, painful ulcers and mouth sores, and abnormally low levels of potassium and magnesium in the blood.

ONCE-DAILY ORAL
LUMAKRAS® (sotorasib) tablets
320 mg | 240 mg | 120 mg
+
Vectibix® (panitumumab)
100mg/5ml | 20mg/ml for injection

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR VECTIBIX® (cont'd)

- Serious or potentially fatal blood clots that traveled to the lungs occurred more in Vectibix®-treated patients, and less than 1% of Vectibix-treated patients died.
- Because of the side effects experienced, patients receiving Vectibix, Avastin, and chemotherapy received less chemotherapy for the first 24 weeks of the study compared with those receiving Avastin and chemotherapy.

Vectibix can cause harm to an unborn child. Use effective birth control to avoid pregnancy while taking Vectibix and for at least 2 months after the last dose.

In patients who received Vectibix alone, the most commonly reported side effects (experienced by 20% or more of patients) were different types of skin rash, infections at the side of the nail beds of the fingers or toes, fatigue (extreme tiredness), nausea, and diarrhea.

In patients who received Vectibix + FOLFOX, the most commonly reported side effects (experienced by 20% or more of patients) were diarrhea, sore mouth, inflammation of mucous membranes, weakness, infection of the nail beds, loss of appetite, low magnesium, low potassium, rash, acne-like skin rash, itching, and dry skin. Serious side effects were diarrhea and dehydration.

Abnormal liver blood tests are common with Lumakras and can sometimes be severe. Lumakras used in combination with Vectibix has led to liver failure and death. Your healthcare provider should do blood tests before starting and during treatment with LUMAKRAS to check your liver function. Tell your healthcare provider right away if you develop any signs or symptoms of liver problems, including: your skin or the white part of your eyes turns yellow (jaundice); dark or "tea-colored" urine; light-colored stools (bowel movements); tiredness or weakness; nausea or vomiting; bleeding or bruising; loss of appetite; or pain, aching, or tenderness on the right side of your stomach-area (abdomen).


The most common side effects of Vectibix when used in combination with Lumakras for CRC include skin rash, dry skin, diarrhea, mouth sores, tiredness, muscle and bone pain, and changes in certain blood tests. These are not all the possible side effects of Vectibix. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please read the **full Prescribing Information** and discuss it with your doctor.

ONCE-DAILY ORAL
LUMAKRAS® (sotorasib) tablets
320 mg | 240 mg | 120 mg
+
Vectibix® (panitumumab)
100mg/5ml | 20mg/ml for injection

Two types of treatment, one destination for support





Your doctor's office will:

- Complete prior authorizations for each therapy
- Review your out-of-pocket costs for each therapy and check for financial assistance
- Advise you when to start **LUMAKRAS**® and schedule your **Vectibix**® infusion appointment

AMGEN® Support+

Visit AmgenSupportPlus.com or call (866) 264-2778, Monday – Friday, 9 am to 8 pm ET to learn more.

Visit Amgen® SupportPlus →

AMGEN

© 2025-2026 Amgen Inc. All rights reserved. Not for reproduction. USA-954-81065 06/26